当前位置:首页 > 报告详情

Tarsus 2025 Update Webcast - Final 1.12.25.pdf

上传人: c** 编号:603993 2025-02-03 20页 1.57MB

1、The Future of Eye CareThe Future of Eye CareBegins HereBegins HereJanuary 2025Matt,an XDEMVYPatient Statements in this presentation about future expectations,plans and prospects,as well as any other statements regarding matters that are not historical facts,may constitute“forward-looking statements.

2、”These include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis,including market size,acceptance,demand,prescription fill rate and adoption rate for XDEMVY;our ability to successfully implement our sales force expansion and new direct-to-consumer camp

3、aign including network TV;our ability to achieve distribution and patient access for XDEMVY;our ability to continue to educate the market about Demodex blepharitis;our ability to continue to drive a successful launch of XDEMVY and become an eye care leader;anticipated regulatory and development mile

4、stones including potential regulatory pathways for approval of XDEMVY in Europe,China,and Japan;the market size and opportunity for our pipeline products including TP-04 for the potential treatment of Ocular Rosacea;the timing of initiation and results of our clinical studies including additional st

5、udies on the impact of XDEMVY,a Japan DB prevalence study,TP-04,and TP-05;the potential regulatory pathways and timing of discussions with regulators including the FDA;the impact of our new sales force representatives on XDEMVY sales;our ability to continue investing in our business,and the quotatio

6、ns of Tarsus management.The words,without limitation,“believe,”“contemplate,”“continue,”“could,”“estimate,”“expect,”“intend,”“may,”“might,”“plan,”“potential,”“predict,”“project,”“should,”“target,”“will,”or“would,”or the negative of these terms or other similar expressions are intended to identify fo

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了Tarsus公司旗下产品XDEMVY在眼部护理领域的应用和前景。XDEMVY是首款且唯一一款FDA批准的针对Demodex blepharitis( Demodex睑炎)的药物,自2025年1月上市以来,已经交付超过104,000瓶,实现净产品销售超过1.13亿美元。据估计,美国有约15-18百万美国人受到Demodex blepharitis的影响。此外,Tarsus还正在开发针对Ocular Rosacea(眼部玫瑰糠疹)的药物TP-04,有望成为该领域的标准治疗方法。公司计划在未来几年内,针对欧洲、中国和日本市场提交XDEMVY的监管批准申请。公司的销售团队已经扩大,并计划实施新的直接面向消费者的广告活动。
"XDEMVY如何改变眼部疾病治疗?" "Tarsus公司如何成为眼科领域的领导者?" "Demodex blepharitis患者有哪些治疗选择?"
客服
商务合作
小程序
服务号
折叠